Sleepio to treat insomnia and insomnia symptoms (MTG70)
Evidence-based recommendations on Sleepio to treat insomnia and insomnia symptoms
Search results
15 results
-
-
Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over (HST20)
Evidence-based recommendations on selumetinib (Koselugo) for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over
-
Elosulfase alfa for treating mucopolysaccharidosis type 4A (HST19)
Evidence-based recommendations on elosulfase alfa (Vimizim) for treating mucopolysaccharidosis type 4A in people of all ages
-
myCOPD for managing chronic obstructive pulmonary disease (MTG68)
Evidence-based recommendations on myCOPD for managing chronic obstructive pulmonary disease
-
UroShield for preventing catheter-associated urinary tract infections (MTG69)
Evidence-based recommendations on UroShield for preventing catheter-associated urinary tract infections
-
Atidarsagene autotemcel for treating metachromatic leukodystrophy (HST18)
Evidence-based recommendations on atidarsagene autotemcel (Libmeldy) for treating metachromatic leukodystrophy in children
-
Otitis media (acute): antimicrobial prescribing (NG91)
This guideline sets out an antimicrobial prescribing strategy for acute otitis media (ear infection). It aims to limit antibiotic use and reduce antimicrobial resistance. Acute otitis media can be caused by viruses or bacteria. It lasts for about a week, and most children get better in 3 days without antibiotics. Serious complications are rare.
-
Prontosan for treating acute and chronic wounds (MTG67)
Evidence-based recommendations on Prontosan for treating acute and chronic wounds
-
3C Patch for treating diabetic foot ulcers (MTG66)
Evidence-based recommendations on 3C Patch for treating diabetic foot ulcers
-
Odevixibat for treating progressive familial intrahepatic cholestasis (HST17)
Evidence-based recommendations on odevixibat (Bylvay) for treating progressive familial intrahepatic cholestasis in people 6 months and older
-
Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care (MTG65)
Evidence-based recommendations on Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care
-
KardiaMobile for detecting atrial fibrillation (MTG64)
Evidence-based recommendations on KardiaMobile for detecting atrial fibrillation
-
Endo-SPONGE for treating low rectal anastomotic leak (MTG63)
Evidence-based recommendations on Endo-SPONGE for treating low rectal anastomotic leak
-
ClearGuard HD antimicrobial barrier caps for preventing haemodialysis catheter-related bloodstream infections (MTG62)
Evidence-based recommendations on ClearGuard HD antimicrobial barrier caps for preventing haemodialysis catheter-related bloodstream infections
-
Synergo for non-muscle-invasive bladder cancer (MTG61)
Evidence-based recommendations on Synergo for non-muscle-invasive bladder cancer